Details for New Drug Application (NDA): 019500
NDA 019500 describes LAMPRENE, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. Additional details are available on the LAMPRENE profile page.
The generic ingredient in LAMPRENE is clofazimine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the clofazimine profile page.
The generic ingredient in LAMPRENE is clofazimine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the clofazimine profile page.
Summary for 019500
| Tradename: | LAMPRENE |
| Applicant: | Novartis |
| Ingredient: | clofazimine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 019500
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LAMPRENE | clofazimine | CAPSULE;ORAL | 019500 | NDA | Novartis Pharmaceuticals Corporation | 0078-1049 | 0078-1049-05 | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (0078-1049-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Dec 15, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 50MG | ||||
| Approval Date: | Dec 15, 1986 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
